The annual Special 301 report of the Office of the United States Trade Representative (USTR) issued today sparked a quick outcry among health advocates over its seemingly more restrictive approach they say bullies other countries into unfairly promoting US pharmaceutical industry rights to an extent that would raise drug prices and limit accessibility.
Go to Source
Author: William New
facebooks